NEUROSCIENCE INSTITUTE AT STANFORD (NIS) September 27, 2004
Dec 22, 2015
NIS: The Rationale• Disorders of the nervous are devastating and
increasingly common.• As a result of advances in basic research, we are
learning to decipher disease mechanisms, encouraging prospects for effective new treatments.
• But, a variety of factors combine to slow the pace of applying the benefits of research to patient care.
A NEW MODEL IS NEEDED TO ACCELERATE RESEARCH LEADING TO TREATMENTS
NIS: The VisionA new culture for neuroscience- that encourages dialogue between scientists, clinicians, patients and industry- that motivates and supports fundamental
neuroscience research- that rapidly translates discoveries into enhanced care for those with disorders of the nervous system- and that sends the message that we are rededicating our efforts to the service of patients.
OutreachEducation
Clinical Care
BasicScience Research
Translational Research
ClinicalResearchNISNIS
To Integrate-To Translate-To Educate
NIS: The Model
To Integrate
-across disciplines
-scientists and clinicians
-professionals and patients/advocates
-across academic institutions
-academia, industry, government
NIS: The Model
To Translate:A Re-Definition
The process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease;
AND
The process of taking insights and ideas developed through the study of human disease to generate new scientific insights.
Bench Bedside
Neurons
Cognition
Neuronalsystems
Genes
Development
• Clinical trials • Industry
Delivery
• Health Care
Neuroscience
Translating Research Advances
Academia Doesn’t Push: Industry Often Doesn’t Pull
Neurons
Cognition
Neuronalsystems
Genes
Development
• Clinical trials • Industry
Delivery
• Health Care
Science
Translating Research Advances in the NIS
Breaking Down Barriers to Progress
NIS: Why Now?• We understand, as never before, how the
brain is built and how it functions.
• We have powerful new tools to further elucidate brain structure and function.
• Recent advances have set the stage for significant improvements in diagnosis and treatment of nervous system disorders.
NIS: Why Here?• The Stanford neuroscience community is
recognized nationally and internationally for its contributions to basic and clinical science.
• It addresses all levels of nervous system investigation.
• Stanford neuroscientists recognize the enormous promise that its work holds for enhancing the lives of patients with neurological and mental disorders.
NIS: Why This Model? Because to accelerate progress the NIS must-
• Foster a culture that recognizes and supports the importance of fundamental and disease-relevant.
• Be able to integrate acrossall levels of analysis of brain function.
• Embrace physician-scientists, clinicians, patients and industry as vital to the effort.
NIS: The Working GroupsInvolve scientists, clinicians, patients, industry
- To focus on solving basic and/or clinical neuroscience problems
- To define the “state of the field”
- To point to knowledge gaps
- To apply resources to fill those gaps
- To accelerate development of tools and concepts
- To accelerate translation to patient care
Investigators: Robert Malenka, Craig Garner, Irving Weissman, Barbara Sommer, Allan Reiss, Dick Tsien, William Mobley.
“Abnormal Synaptic Structure and Function in Down Syndrome: Elucidating Genetic, Molecular and Cellular Mechanisms Leading to Treatments to Enhance Cognition”
Working Group on Down Syndrome
Discovers genes and mechanisms
Discoverstreatments
Defines the problems
Delivers treatments
THE WORKING GROUP
Stroke - Greg Albers, Gary Steinberg, Michael Moseley,
Pak Chan, Robert Sapolsky Parkinson’s Disease- Theo Palmer, Rich Reimer, Helen Bronte-Stewart,
Jamie HendersonDevelopmental Motor Disorders-Terry Sanger, Scott Delp, Krishna ChenoyPain- Sean Mackey, Dave Yeomans
Working Groups in the Making
Alzheimer’s Disease- Tony Wyss-Coray, Mike Grecius, Bill MobleyMultiple Sclerosis/Neural Regeneration- Ben Barres, Larry SteinmanBrain Tumor- Larry Recht, Griff Harsh, Mark SchnitzerSleep-Emmanuel Mignot, Craig HellerEpilepsy- Robert Fisher, John Huguenard
Working Groups in the Making